Algorithm-Guided Insulin Dosing Improves Blood Sugar Control in Type 2 Diabetes

Key Takeaways:

• An algorithm paired with continuous glucose monitoring significantly increased time in target glucose range compared with standard self-monitoring approaches
  
• The tool provides personalised weekly insulin dose recommendations based on recent glucose data, helping to simplify titration
  
• Early findings suggest strong patient acceptability and potential to enhance diabetes management at scale, though larger trials are needed
  
  
  

A data-driven approach to insulin adjustment

A novel algorithm developed by researchers at the University of Virginia Center for Diabetes Technology has demonstrated encouraging results in supporting people living with Type 2 Diabetes to better manage their blood glucose levels.

The system works in combination with a continuous glucose monitor and provides tailored recommendations for insulin dose adjustments. Rather than relying solely on manual interpretation of glucose readings, the algorithm analyses patterns over time and offers structured, data-informed guidance.

In a clinical trial involving 30 participants, individuals were randomly assigned to one of two approaches over a 16-week period:

• Algorithm-guided insulin adjustment using continuous glucose monitoring data
  
• Traditional self-monitoring of blood glucose with independent dose adjustment
  

The results showed a marked improvement in glycaemic control among those using the algorithm. Participants in this group increased their average time spent within a safe blood glucose range from 54.1% to 75.3%. By contrast, those relying on self-monitoring alone saw a more modest increase from 50.2% to 55.3%.

Moving beyond traditional insulin management

The findings highlight the growing role of digital health tools in diabetes care. According to Marc D. Breton, the study’s lead author:

“These results clearly show that diabetes technology and advanced algorithms can be leveraged to great effects, well beyond the classical paradigm of automated insulin delivery. As continuous glucose monitoring and connected medical devices become ubiquitous, we have the opportunity to provide highly personalized advice and monitoring to people with diabetes and guide their use of insulin and medications. Showing the impact of these technologies in early insulin therapy (only one dose a day) opens the door to helping the vast majority of people using insulin, well beyond what we were able to achieve with automated insulin delivery.”

This perspective reflects a broader shift towards personalised, technology-enabled care. Rather than fully automated systems alone, there is increasing interest in decision-support tools that augment clinical judgement and patient self-management.

Addressing the challenges of insulin titration

For many people living with type 2 diabetes, treatment often begins with oral or non-insulin therapies. However, as the condition progresses, insulin may become necessary to maintain adequate glycaemic control.

Adjusting insulin doses – a process known as titration – can be complex and burdensome. It typically requires frequent monitoring, interpretation of glucose patterns, and iterative dose changes. Importantly, there is no universally standardised titration protocol, which can create variability in care and outcomes.

To address this, Anas El Fathi developed the algorithm with the aim of streamlining and improving this process. The system evaluates two weeks of continuous glucose monitoring data and generates weekly recommendations for insulin dose adjustments, offering a structured and personalised approach.

Strong acceptance and clinical potential

The study also explored how well the technology was received by participants. According to Ralf Nass:

“From a medical point of view, it was fascinating to see that the algorithm was not only better than the standardized insulin titration recommendations, but also how well the technology was accepted by the participants with type 2 diabetes. This type of technology has the potential to help physicians enable their patients to achieve better glycemic control faster by using a personalized approach.”

This combination of improved outcomes and user acceptability is particularly important, as adherence and engagement remain key challenges in long-term diabetes management.

Future directions – towards more personalised diabetes care

While the results are promising, the researchers emphasise that further validation is required. Larger and longer clinical trials will be needed to confirm the effectiveness of the algorithm across more diverse populations.

Looking ahead, the integration of more advanced data-driven approaches may further enhance personalisation. Breton noted:

“It is only the very beginning of these efforts. With early demonstration behind us, we can focus on robust approaches that will be effective with more varied populations. Integrating recently developed data-driven methodologies, especially digital twins, to further improve our capacity to tailor diabetes managements to individuals is likely to once more revolutionize diabetes care.”

Such developments could represent a significant step forward in precision medicine for people living with diabetes.

Study publication and funding

The findings have been published in the peer-reviewed journal Diabetes Technology & Therapeutics, with the article available as open access.

The research team included El Fathi, Nass, Carol J. Levy, Camilla Levister, Grenye O’Malley, Nirali A. Shah, Shaziah Hassan, Cheryl Quainoo, Chaitanya L.K. Koravi, Taylor N. Nguyen, Giulio Matteo Santini, Emma Emory, Carlene Alix, Dillon K. Flanagan, David Fulkerson, Mary Clancy Oliveri, Christian Laugesen, Jonas K. Lineolov, Peter W. Hansen and Breton.

The clinical trial was supported by a grant from Novo Nordisk.